In pathobiology, increased de novo galanin expression is postulated to reduce circuit excitation in pain (analgesia) [48] and epilepsy (anticonvulsant action) [31], an observation also supported by the pharmacological modulation of galanin receptors in disease states and models. The gene discussed is GAL; the disease is epilepsy.